Michael West - AgeX Therapeutics Chief Executive Officer, Founder, Director
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
CEO
Dr. Michael D. West, Ph. D., is Chief Executive Officer, Founder, Director of the Company. West, has devoted his entire career to unraveling the mystery of the biological clock from his scientific training with a focus on the biology of cellular aging, to his founding of Geron, to helming other successful biotechnology companies with a focus on immortal pluripotent cellular therapies, to authoring a popular book on human aging. AgeX and its clinical programs represent the culmination of his nearly three decades of research and development into the aging process. Dr. West has served as coCEO of AgeX parent company, BioTime, Inc. since 2015, and before that as CEO, starting in 2007. From 1998 to 2007, Dr. West served as CEO, President, and Chief Scientific Officer of Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma of Japan in early 2016. In 1990 Dr. West founded Geron Corporationration, which was probably the first regenerative medicine startup, with backing from VC firms from Kleiner Perkins Caufield Byers, Venrock and others. For the companys scientific team he recruited Elizabeth Blackburn, Carol Greider and Jack Szostak, who collectively went on to win the 2009 Nobel Prize in Physiology or Medicine, and for its scientific and clinical advisory board he recruited Nobel Laureates Carol Greider and James Watson, as well as Leonard Hayflick and others. While at Geron Dr. West also created the research consortium with Drs. James Thomson and John Gearhart that led to the first isolation of human embryonic stem cells. Dr. West was a member of BioTimes Board of Directors since 2002, is a Director of Asterias Biotherapeutics and was a Director of OncoCyte Corporationration from 2013 to 2016 since 2017.
| Age | 71 |
| Tenure | 7 years |
| Phone | 510 671 8370 |
| Web | https://www.agexinc.com |
Michael West Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael West against AgeX Therapeutics stock is an integral part of due diligence when investing in AgeX Therapeutics. Michael West insider activity provides valuable insight into whether AgeX Therapeutics is net buyers or sellers over its current business cycle. Note, AgeX Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell AgeX Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael West over three months ago Acquisition by Michael West of 1333 shares of Transcat subject to Rule 16b-3 | ||
Michael West over six months ago Acquisition by Michael West of 3125 shares of AgeX Therapeutics subject to Rule 16b-3 |
AgeX Therapeutics Management Efficiency
The company has Return on Asset of (0.8188) % which means that on every $100 spent on assets, it lost $0.8188. This is way below average. AgeX Therapeutics' management efficiency ratios could be used to measure how well AgeX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.AgeX Therapeutics has 4.37 M in debt with debt to equity (D/E) ratio of 0.75, which is OK given its current industry classification. AgeX Therapeutics has a current ratio of 0.19, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AgeX to invest in growth at high rates of return.
Similar Executives
| Found 8 records | CEO Age | ||
| Marcio MBA | Praxis Precision Medicines | 45 | |
| MBA MA | Lineage Cell Therapeutics | 53 | |
| Adrian Gottschalk | Foghorn Therapeutics | 48 | |
| Clay Siegall | Immunome | 63 | |
| Carole MD | Larimar Therapeutics | 65 | |
| Heidi MS | Invivyd | N/A | |
| Maria Palasis | Lyra Therapeutics | 59 | |
| Michael Brigham | ImmuCell | 63 | |
Management Performance
| Return On Asset | -0.82 |
AgeX Therapeutics Leadership Team
Elected by the shareholders, the AgeX Therapeutics' board of directors comprises two types of representatives: AgeX Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AgeX. The board's role is to monitor AgeX Therapeutics' management team and ensure that shareholders' interests are well served. AgeX Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AgeX Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| EunJae CPA, Chief Officer | ||
| Alfred Kingsley, Chairman of the Board | ||
| Judith Segall, Secretary | ||
| Michael West, Chief Executive Officer, Founder, Director | ||
| Aubrey Grey, Vice President - New Technology Discovery | ||
| Gregory Bailey, Independent Chairman of the Board | ||
| Ivan Labat, Chief Information Officer | ||
| Joanne Hackett, Interim Board | ||
| Hal Sternberg, Vice President - Research | ||
| Nafees MD, Chief Officer | ||
| Andrea Park, Chief Financial Officer | ||
| Annalisa Jenkins, Independent Director | ||
| Michael May, Independent Director |
AgeX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AgeX Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.82 | |||
| Operating Margin | (63.57) % | |||
| Current Valuation | 33.33 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 75.73 % | |||
| Shares Owned By Institutions | 5.64 % | |||
| Number Of Shares Shorted | 4.47 K | |||
| Price To Earning | (5.95) X | |||
| Price To Book | 12.96 X | |||
| Price To Sales | 221.90 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in AgeX Stock
If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |